REVVITY, INC.

Life Sciences

Revenue for the three months ended October 4, 2026 was $379.6 million, as compared to $342.8 million for the three months ended September 28, 2025, an increase of $36.8 million, or 11%. The increase in our Life Sciences segment revenue during the three months ended October 4, 2026 was driven by an increase of $21.6 million in Life Sciences Solutions revenue and an increase of $15.2 million in Software revenue.

Revenue for the nine months ended October 4, 2026 was $1,100.1 million, as compared to $1,049.1 million for the nine months ended September 28, 2025, an increase of $51.0 million, or 5%. The increase in our Life Sciences segment revenue during the nine months ended October 4, 2026 was driven by an increase of $38.1 million in Life Sciences Solutions revenue and an increase of $12.9 million in Software revenue. Our Life Sciences segment benefited from an extra fiscal week for the nine months ended October 4, 2026.

Segment operating income for the three months ended October 4, 2026 was $119.5 million, as compared to $101.0 million for the three months ended September 28, 2025, an increase of $18.4 million, or 18%. Segment operating margin increased 200 basis points in the three months ended October 4, 2026, as compared to the three months ended September 28, 2025, primarily due to favorable product mix shift and increased volume leverage.

Segment operating income for the nine months ended October 4, 2026 was $335.0 million, as compared to $322.2 million for the nine months ended September 28, 2025, an increase of $12.8 million, or 4%. Segment operating margin decreased 30 basis points in the nine months ended October 4, 2026, as compared to the nine months ended September 28, 2025, primarily due to strategic investments in software and new product development and impact of the extra fiscal week in the nine months ended October 4, 2026.

Diagnostics

Revenue for the three months ended October 4, 2026 was $349.3 million, as compared to $356.1 million for the three months ended September 28, 2025, a decrease of $6.8 million, or 2%. Thedecrease in our Diagnostics segment revenue duringthe three months ended October 4, 2026 was driven by a decrease of $10.5 million in Immunodiagnostics revenue, partially offset by an increase of $3.7 million in Reproductive Health revenue.

Revenue for the nine months ended October 4, 2026 was $1,069.6 million, as compared to $1,034.9 million for the nine months ended September 28, 2025, an increase of $34.7 million, or 3%. Theincrease in our Diagnostics segment revenue duringthe nine months ended October 4, 2026 was driven by an increase of $45.0 million in Reproductive Health revenue, partially offset by a decrease of $10.3 million in Immunodiagnostics revenue. Our Diagnostics segment benefited from an extra fiscal week in the nine months ended October 4, 2026.

Segment operating incomefor the three months ended October 4, 2026 was $104.3 million, as compared to $89.4 millionfor the three months ended September 28, 2025, an increase of $14.9 million, or 17%. Segment operating margin increased 480 basis points in the three months ended October 4, 2026, as compared to the three months ended September 28, 2025, primarily due to restructuring benefit and cost containment initiatives.

Segment operating incomefor the nine months ended October 4, 2026 was $293.3 million, as compared to $252.8 millionfor the nine months ended September 28, 2025, an increase of $40.5 million, or 16%. Segment operating margin increased 300 basis points in the nine months ended October 4, 2026, as compared to the nine months ended September 28, 2025, primarily due to tariff refunds, restructuring benefit, and cost containment initiatives, partially offset by product mix shift and the impact of the extra fiscal week in the nine months ended October 4, 2026.